Log In
BCIQ
Print this Print this
 

IAB22M2C

  Manage Alerts
Collapse Summary General Information
Company ImaginAb Inc.
DescriptionCD8 T cell imaging agent
Molecular Target CD8A (p32) (CD8)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationCancer, Diagnostic
Indication DetailsDetect CD8 T cell distribution as a measure of immune response in patients with cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/13/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today